Alembic Pharmaceuticals (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ticagrelor Tablets, ...

If approved, the targeted IGF-1 fusion protein would become the only treatment available for late-window stroke patients ...

Key Highlights Scp776 is the first therapy to show clinically meaningful efficacy in late-window stroke patients (treated up ...

Financing supports execution of Phase 2b RAISE trial evaluating BB-031, an investigational reversible thrombolytic for acute ...

LOS ANGELES -- The HOPE trial made another case for extending the therapeutic window for IV thrombolysis in acute ischemic stroke, potentially widening the pool of people eligible for therapy. Among ...

Abstract: Assessing motor abilities is crucial for the rehabilitation of post-stroke patients. However, in practical scenarios, medical data often suffer from issues like limited sample size and low ...

A major U.K. study of more than 165,000 dementia patients has found that risperidone raises stroke risk without exception, challenging safety assumptions by leaving no "safe group." The powerful ...

HONG KONG, Sept. 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its global, multicenter ...

Federal immigration authorities detained a woman seeking medical care at the National Institutes of Health’s flagship research hospital, according to an internal document and an NIH official briefed ...

Patient numbers at NIH Clinical Center dropped significantly from February to April, coinciding with staff layoffs and policy changes. The number of cancer trial participants decreased by about 20 ...

University of California Los Angeles (UCLA) Department of Neurology, Los Angeles, CA, United States The Heads Up test, initially described in 2017, offers a potential tool for assessing likelihood of ...